摘要
背景:过去的二十年中,数据支持了阿尔茨海默病的两个假设,即β-淀粉样蛋白假说和“蛋白-蛋白”假说。无疑,Aβ 和 tau 蛋白是目前治疗AD的主要方法。不幸的是,很少有这种治疗方法成功的案例。基于这一点,我们将讨论深部脑刺激作为一种很有前途的治疗策略,旨在恢复大脑活动。最后,在认知缺陷修复的范围,我们将讨论边缘形成的相关性作为脑深部电刺激的有潜力的神经解剖学靶点。 方法:改良tau的免疫组织化学(磷酸化程度 ser199-202–Thr205,AT8抗体标记) 在石蜡包埋人脑切片上进行了研究。对FT病理提供了详细的表征。 结果:异常磷酸化tau蛋白是许多脑疾病如阿尔茨海默病的关键的共同标志,如帕金森病、Pick病、唐氏综合症和额颞叶痴呆及能够影响对记忆的形成至关重要的突触活动。有了这一想法,旨在恢复突触事件的治疗策略,可以提供更好的结果。 结论:目前的治疗方法并不十分理想,以及对脑疾病机制缺乏的基本知识,迫使我们寻求新的替代品以受益于患者。有趣的是,神经刺激的方法已经用于治疗一些运动功能障碍,与目前的阿尔茨海默氏症的治疗相比,深部脑刺激不直接干扰正常的蛋白质功能,因此增加了成功的概率。
关键词: β-淀粉样蛋白,脑疾病,神经刺激,磷酸化,突触失效,突触可塑性,tau蛋白,治疗靶点
Current Alzheimer Research
Title:Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Volume: 14 Issue: 1
Author(s): Siddhartha Mondragón-Rodríguez, George Perry, Fernando Pena-Ortega, Sylvain Williams
Affiliation:
关键词: β-淀粉样蛋白,脑疾病,神经刺激,磷酸化,突触失效,突触可塑性,tau蛋白,治疗靶点
摘要: Background: The last two decades have seen a great advance in the data that supports the two current hypotheses in Alzheimer's disease field, the amyloid beta hypothesis and the tau hypothesis. Not surprisingly, Aβ and tau proteins are currently the major therapeutic research targets for AD treatment. Unfortunately, nothing but moderate success has emerged from such therapeutic approaches. With this in mind, we will discuss deep brain stimulation as a promising therapeutic strategy that aims to restore brain activity. Lastly, in the scope of cognitive deficit restoration, we will discuss the relevance of the limbic formation as a promising neuroanatomical target for deep brain stimulation.
Methods: Immunohistochemistry for modified tau (phosphorylated at Ser199–202–Thr205 labelled by the antibody AT8) was performed on paraffin-embedded human brain sections providing a detailed characterization of NFT pathology. Results: Abnormally phosphorylated tau protein is the key common marker in several brain diseases such as Alzheimer's disease, Parkinson's disease, Pick Disease, Down syndrome and frontotemporal dementia and is capable of affecting synaptic events that are critical for memory formation. With this in mind, therapeutic strategies aiming to restore synaptic events could offer better outcomes. Conclusion: The humble success of current therapeutic strategies along with the lack of basic knowledge of the brain disease mechanisms calls for alternatives that benefit patients in the present moment. One of particular interest is the neurostimulation strategy that is already a well-established treatment for several movement disorders and when compared to current Alzheimer's therapeutic strategies, deep brain stimulation does not directly interfere with the normal protein function, therefore increasing the probability of success.Export Options
About this article
Cite this article as:
Siddhartha Mondragón-Rodríguez, George Perry, Fernando Pena-Ortega, Sylvain Williams , Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease, Current Alzheimer Research 2017; 14 (1) . https://dx.doi.org/10.2174/1567205013666160819131336
DOI https://dx.doi.org/10.2174/1567205013666160819131336 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Current Drug Safety Cannabinoids
Current Drug Targets - CNS & Neurological Disorders SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology Hippocampal Morphology and Autobiographic Memory in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Herbal and Holistic Solutions for Neurodegenerative and Depressive Disorders: Leads from Ayurveda
Current Pharmaceutical Design Does the Vitamin D Deficiency Have Any Role in Severity or Prolongation of Seizure? A Pilot Study in Iran
Current Nutrition & Food Science Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling
Current Neuropharmacology Neutralization of Interleukin-1β Reduces Vasospasm and Alters Cerebral Blood Vessel Density Following Experimental Subarachnoid Hemorrhage in Rats
Current Neurovascular Research Decreased Expression of Sox-1 in Cerebellum of Rat with Generalized Seizures Induced by Kindling Model
CNS & Neurological Disorders - Drug Targets Contribution of Analytical Microscopies to Human Neurodegenerative Diseases Research (PSP and AD)
Mini-Reviews in Medicinal Chemistry Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering Melatonin Effects in REM Sleep Behavior Disorder Associated with Obstructive Sleep Apnea Syndrome: A Case Series
Current Alzheimer Research Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets The Role of Oxazolidine Derivatives in the Treatment of Infectious and Chronic Diseases
Current Bioactive Compounds N-3 (Omega-3) Polyunsaturated Fatty Acids in the Pathophysiology and Treatment of Depression: Pre-Clinical Evidence
CNS & Neurological Disorders - Drug Targets The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Neuropharmacology